PITTSBURGH, March 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2012, as filed with the U.S. Securities and Exchange Commission on Feb. 28, 2013, is available through its Web site ( www.mylan.com). In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request to Investor Relations at 724.514.1813.
This press release is being issued pursuant to NASDAQ Listing Rule 5250(d)(1)(C).
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside.
SOURCE Mylan Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts